in its principle embodiment the present invention provides a powder for oral suspension of cefdinir comprising greater than 4 . 2 % by weight of cefdinir . in another embodiment the present invention provides a powder for oral suspension of cefdinir comprising between about 6 % to about 10 % by weight of cefdinir . in another embodiment the present invention provides a powder for oral suspension of cefdinir comprising at least 8 . 4 % by weight of cefdinir . in another embodiment the present invention provides a powder for oral suspension of cefdinir comprising in another embodiment the present invention provides a powder for oral suspension of cefdinir comprising : in another embodiment the present invention provides an powder for oral suspension of cefdinir comprising : the present invention also teaches a method of treating acute bacterial otitis media , pharyngitis and tonsillitis with a oral suspension of cefdinir wherein said suspension is made by reconstituting a powder comprising greater than 4 . 2 % by weight of cefdinir . a further embodiment of the present invention teaches a method of treating acute bacterial otitis media , pharyngitis and tonsillitis with a oral suspension of cefdinir wherein said suspension is made by reconstituting a powder comprising at least 8 . 4 % cefdinir . all publications , issued patents , and patent applications cited herein are hereby incorporated by reference in their entirety . in the case of inconsistencies , the present disclosure , including definitions , will prevail . as used herein , the singular forms “ a ”, “ an ”, and “ the ” include plural reference unless the context clearly dictates otherwise . as used in the present specification the following terms have the meanings indicated : the term “ buffering agent ,” as used herein , refers to an agent or a mixture of agents that can maintain the original acidity or basicity of a composition . representative buffering agents include , but are not limited to , citric acid , sodium citrate , sodium phosphate , potassium citrate , and mixtures thereof . a preferred buffering agent of the present invention is a mixture of citric acid and sodium citrate . the term “ diluent ,” as used herein , refers to an agent or mixture of agents that when added to a formulation makes that formulation thinner or less concentrated and may also improve manufacturability . diluents of the present invention can also serve other functions . for example , a diluent can also serve as a sweetener . representative diluents include , but are not limited to , sucrose , sorbitol , xylitol , dextrose , fructose , malitol , sugar potassium , aspartame , saccharin , saccharin sodium , and mixtures thereof . a preferred diluent of the present invention is sucrose . the term “ flavoring agent ,” as used herein , refers to an agent or a mixture of agents that adds flavor to a mixture . representative flavoring agents include , but are not limited to , artificial strawberry flavor and artificial cream flavor . the term “ glidant ,” as used herein , refers to an agent or a mixture of agents that facilitates the flow of powders in the manufacturing process . representative glidants include , but are not limited to , colloidal silicon dioxide , talc , fumed silica , magnesium stearate , calcium stearate , magnesium trisilicate , powdered cellulose , starch , tribasic calcium phosphate , and mixtures thereof . a preferred glidant of the present invention is colloidal silicon dioxide . the term “ lubricant ,” as used herein refers to an agent or a mixture of agents that lessens or prevents friction . representative lubricants include , but are not limited to , magnesium stearate , calcium stearate , zinc stearate , magnesium oxide , stearic acid , sodium stearyl fumarate , sodium lauryl stearate , hydrogenated vegetable oil , corn starch , colloidal silicon dioxide , talc , and mixtures thereof . a preferred lubricant of the present invention is magnesium stearate . the term “ preservative ,” as used herein , refers to an agent or mixture of agents that is used to protect a composition against antimicrobial ( e . g ., yeast , mold , bacteria ) activity . representative preservatives include , but are not limited to , sodium benzoate , benzoic acid , ethylenediaminetetraacetic acid , sorbic acid , benzethonium chloride , benzalkonium chloride , bronopol , butyl paraben , methyl paraben , ethylparaben , propyl paraben , thiomerosol , sodium propionate , chlorhexidine , chlorobutanol , chlorocresol , cresol , imidurea , phenol , phenylmercuric salts , potassium sorbate , propylene glycol , and mixtures thereof . a preferred preservative of the present invention is sodium benzoate . the term “ viscosity enhancer ,” as used herein , refers to an agent or a mixture of agents that increases the thickness of a liquid thereby making it slow to flow . for example , in a suspension a viscosity enhancer will help to keep the active ingredient suspended to allow accurate dosing . representative viscosity enhancers include , but are not limited to , xantham gum , guar gum , acacia , povidone , alginic acid , sodium alginate , propylene glycol alginate , carbomer , carboxymethylcellulose calcium , carboxymethylcellulose sodium , ethylcellulose , gelatin , ethylcellulose , hydroxyethyl cellulose , hydroxypropyl cellulose , polydextrose , carrageenan , methylcellulose , sucrose , sorbitol , xylitol , dextrose , fructose , malitol , sugar , sodium alginate , tragacanth , hydroxypropyl methylcellulose , bentonite , a polyvinyl alcohol , cetearyl alcohol , colloidal silicon dioxide , and mixtures thereof . a preferred viscosity enhancer of the present invention is a mixture of xantham gum and guar gum . cefdinir can be prepared according to the procedures described in u . s . pat . ser . no . 4 , 935 , 507 , issued jun . 19 , 1990 and u . s . pat . ser . no . 4 , 559 , 334 , issued dec . 17 , 1985 , both herein fully incorporated by reference . example 1 shows the percentage amounts used in the preparation of an 8 % cefdinir oral powder formulation . as mentioned earlier , the current marketed omnicef ® for suspension is a 4 % ( 4 . 2 % actual ) cefdinir powder by weight . the 8 % formula was bioequivalent to the omnicef ® for oral suspension product . examples 2 and 3 show percentage amounts that can be used in the preparation of 6 % and 10 % cefdinir oral powder formulations .
the present invention discloses a novel powder for oral suspension of cefdinir . also disclosed are methods of preparing the suspension and methods of treatment using the suspension .